SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.580
+0.020 (1.28%)
Apr 17, 2026, 4:08 PM HKT
SinoMab BioScience Market Cap
SinoMab BioScience has a market cap or net worth of 2.16 billion as of April 17, 2026. Its market cap has increased by 61.09% in one year.
Market Cap
2.16B
Enterprise Value
2.13B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
1.58
Market Cap Chart
Since November 12, 2019, SinoMab BioScience's market cap has decreased from 6.04B to 2.16B, a decrease of -64.17%. That is a compound annual growth rate of -14.75%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 2.16B | 16.42% |
| Dec 31, 2025 | 1.86B | 56.14% |
| Dec 31, 2024 | 1.19B | -31.56% |
| Dec 29, 2023 | 1.74B | -7.18% |
| Dec 30, 2022 | 1.87B | -34.91% |
| Dec 31, 2021 | 2.88B | -37.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Nov 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 3.15B |
| Medtide | 3.13B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 2.61B |
| Immunotech Biopharm | 2.24B |
| Frontage Holdings | 2.11B |
| HighTide Therapeutics | 2.09B |
| Mabpharm | 1.81B |
| Cutia Therapeutics | 1.76B |